TY - JOUR
T1 - Initial diagnostic workup of acute Leukemia guideline from the College of American pathologists and the American Society of Hematology
AU - Arber, Daniel A.
AU - Borowitz, Michael J.
AU - Cessna, Melissa
AU - Etzell, Joan
AU - Foucar, Kathryn
AU - Hasserjian, Robert P.
AU - Rizzo, J. Douglas
AU - Theil, Karl
AU - Wang, Sa A.
AU - Smith, Anthony T.
AU - Rumble, R. Bryan
AU - Thomas, Nicole E.
AU - Vardiman, James W.
N1 - Funding Information:
Seattle Genetics, Bothell, Washington Seattle Genetics, Bothell, Washington Cancer Incite LLC, San Antonio, Texas GlaxoSmithKline Inc, Brentford, Middlesex, United Kingdom Amirsys, Salt Lake City, Utah Abbreviations: AACC, American Association for Clinical Chemistry; AAOMP, American Association of Oral & Maxillofacial Pathology; ASCP, American Society for Clinical Pathology; AMP, Association for Molecular Pathology; ARP, American Registry of Pathology; ASBMT, American Society for Blood and Marrow Transplantation; ASCO, American Society of Clinical Oncology; ASH, American Society of Hematology; CAP, College of American Pathologists; CDC, Centers for Disease Control and Prevention; CLSI, Clinical & Laboratory Standards Institute; HRSA, Health Resources and Services Administration; ISLH, International Society for Laboratory Hematology; MEDCAC, Medicare Evidence Development & Coverage Advisory Committee; NCI, National Cancer Institute; NIH, National Institutes of Health; NHLBI, National Heart, Lung, and Blood Institute; USCAP, United States and Canadian Academy of Pathology; US FDA, United States Food and Drug Administration. a Anthony T. Smith, MLS has no reported conflicts of interest to disclose.
Funding Information:
Celgene, Summit, New Jersey Gerson Lehrman Group, New York, New York Glenview Capital, New York, New York United States Diagnostic Standards, Rockville, Maryland Clariant, Muttenz, Switzerland DAVA Oncology, Dallas, Texas Bristol-Myers Squibb, New York, New York Agios Pharmaceuticals, Cambridge, Massachusetts Celgene, Summit, New Jersey Novartis, Deerfield, Illinois AMP, Bethesda, Maryland California Society of Pathologists, Sacramento CAP, Northfield, Illinois Emory University, Atlanta, Georgia Minnesota Society of Pathologists, Minneapolis, Minnesota South Bay Pathology Society, San Jose, California USCAP, Palm Springs, California University of Calgary, Calgary, Alberta, Canada Montefiore Medical Center, Bronx, New York Brigham and Women’s Hospital, Boston, Massachusetts Cleveland Clinic, Cleveland, Ohio Tutorial in Neoplastic Hematopathology, Miami, Florida (2017) University of Chicago, Chicago, Illinois ASCP, Chicago, Illinois The France Foundation, Old Lyme, Connecticut ISLH, Glenview, Illinois Memorial Sloan Kettering Cancer Center, New York, New York Medical University of South Carolina, Charleston University of Texas Southwestern Medical Center, Dallas Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania Georgia Regents University Medical Center, Augusta AAOMP, Wheaton, Illinois Baumgartner Nelson & Wagner PLLC, Vancouver, Washington Dade County, Florida/Fowler White Burnett, Miami, Florida The Markham Group, Spokane, Washington The Berkowitz Law Firm LLC, Stamford, Connecticut Malkmus Law Firm LLC, Springfield, Missouri Gary D. McCallister & Associates LLC, Chicago, Illinois Christie Pabarue Mortensen & Young, Philadelphia, Pennsylvania ASCP Press, Chicago, Illinois Elsevier, Atlanta, Georgia Lippincott Williams & Wilkins (now Wolters Kluwer), Riverwoods, Illinois Society for Hematopathology, Chicago, Illinois USCAP, Palm Springs, California HTG Molecular Diagnostics, Inc, Tucson, Arizona
PY - 2017/10
Y1 - 2017/10
N2 - Context. - A complete diagnosis of acute leukemia requires knowledge of clinical information combined with morphologic evaluation, immunophenotyping and karyotype analysis, and often, molecular genetic testing. Although many aspects of the workup for acute leukemia are well accepted, few guidelines have addressed the different aspects of the diagnostic evaluation of samples from patients suspected to have acute leukemia. Objective. - To develop a guideline for treating physicians and pathologists involved in the diagnostic and prognostic evaluation of new acute leukemia samples, including acute lymphoblastic leukemia, acute myeloid leukemia, and acute leukemias of ambiguous lineage. Design. - The College of American Pathologists and the American Society of Hematology convened a panel of experts in hematology and hematopathology to develop recommendations. A systematic evidence review was conducted to address 6 key questions. Recommendations were derived from strength of evidence, feedback received during the public comment period, and expert panel consensus. Results. - Twenty-seven guideline statements were established, which ranged from recommendations on what clinical and laboratory information should be available as part of the diagnostic and prognostic evaluation of acute leukemia samples to what types of testing should be performed routinely, with recommendations on where such testing should be performed and how the results should be reported. Conclusions. - The guideline provides a framework for the multiple steps, including laboratory testing, in the evaluation of acute leukemia samples. Some aspects of the guideline, especially molecular genetic testing in acute leukemia, are rapidly changing with new supportive literature, which will require on-going updates for the guideline to remain relevant.
AB - Context. - A complete diagnosis of acute leukemia requires knowledge of clinical information combined with morphologic evaluation, immunophenotyping and karyotype analysis, and often, molecular genetic testing. Although many aspects of the workup for acute leukemia are well accepted, few guidelines have addressed the different aspects of the diagnostic evaluation of samples from patients suspected to have acute leukemia. Objective. - To develop a guideline for treating physicians and pathologists involved in the diagnostic and prognostic evaluation of new acute leukemia samples, including acute lymphoblastic leukemia, acute myeloid leukemia, and acute leukemias of ambiguous lineage. Design. - The College of American Pathologists and the American Society of Hematology convened a panel of experts in hematology and hematopathology to develop recommendations. A systematic evidence review was conducted to address 6 key questions. Recommendations were derived from strength of evidence, feedback received during the public comment period, and expert panel consensus. Results. - Twenty-seven guideline statements were established, which ranged from recommendations on what clinical and laboratory information should be available as part of the diagnostic and prognostic evaluation of acute leukemia samples to what types of testing should be performed routinely, with recommendations on where such testing should be performed and how the results should be reported. Conclusions. - The guideline provides a framework for the multiple steps, including laboratory testing, in the evaluation of acute leukemia samples. Some aspects of the guideline, especially molecular genetic testing in acute leukemia, are rapidly changing with new supportive literature, which will require on-going updates for the guideline to remain relevant.
UR - http://www.scopus.com/inward/record.url?scp=85021786349&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021786349&partnerID=8YFLogxK
U2 - 10.5858/arpa.2016-0504-CP
DO - 10.5858/arpa.2016-0504-CP
M3 - Review article
C2 - 28225303
AN - SCOPUS:85021786349
SN - 0003-9985
VL - 141
SP - 1342
EP - 1393
JO - Archives of Pathology and Laboratory Medicine
JF - Archives of Pathology and Laboratory Medicine
IS - 10
ER -